20-F: Mainz Biomed N.V. Reports Annual Results for Fiscal Year 2024, Focuses on ColoAlert Expansion and U.S. Market Entry

Mainz Biomed N.V. announces its annual results for the fiscal year ended December 31, 2024, highlighting a strategic shift towards European market expansion and preparations for U.S. market entry.

Summary

• Mainz Biomed N.V. reported its annual results for the fiscal year ended December 31, 2024.
• The company is focusing on expanding its ColoAlert business in Europe and preparing for U.S. market entry.
• Net losses for 2024 were $21.65 million, compared to $26.29 million in 2023.
• Revenue remained relatively stable at $893,991 in 2024 compared to $895,479 in 2023.
• ColoAlert sales through the lab network increased by 33% to $562,507 in 2024.
• Direct-to-consumer sales decreased by 34% to $272,813 as the company exited that business.
• Research and development expenses decreased by 39% to $5.84 million in 2024.
• Sales and marketing expenses increased by 7% to $6.58 million in 2024.
• General and administrative expenses decreased by 42% to $6.57 million in 2024.
• The company had $6.24 million in cash and cash equivalents as of December 31, 2024.
• The company plans to fund its cash flow and working capital needs through current cash on hand and future debt and/or equity financings.
• The company restructured its operations in July and October 2024, reducing personnel by 65% and external consulting costs.
• The company sold its European Oncology Lab (EOL) business in St. Ingbert, Germany.
• The company amended the employment contracts of its CEO and CFO, reducing their salaries.
• The company believes that these cost reductions will best position our business for 2025 and beyond.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is taking steps to improve its financial position and expand its market reach, it is still facing significant challenges, including recurring losses and substantial doubt about its ability to continue as a going concern.

Positives

• ColoAlert sales through the lab network increased by 33% to $562,507 in 2024, indicating growing market acceptance through this channel.
• Research and development expenses decreased by 39% to $5.84 million in 2024, suggesting improved efficiency in R&D spending.
• General and administrative expenses decreased by 42% to $6.57 million in 2024, reflecting successful cost reduction efforts.
• The company restructured its operations, reducing personnel by 65% and external consulting costs, which should lead to lower operating expenses in the future.
• The company had $6.24 million in cash and cash equivalents as of December 31, 2024, providing a financial cushion for ongoing operations.
• The company is focusing on expanding its ColoAlert business in Europe and preparing for U.S. market entry, which could drive future revenue growth.

Negatives

• The company experienced recurring losses, with an accumulated deficit totaling $91.0 million as of December 31, 2024.
• The company had negative cash flows used in operating activities of $17.1 million for the year ended December 31, 2024.
• Direct-to-consumer sales decreased by 34% to $272,813 as the company exited that business, indicating a loss of revenue from this channel.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• The company faces competition from providers of more traditional CRC screening diagnostics, such as colonoscopies, as well as other manufacturers of non-invasive stoolor blood-based tests.
• The company's success depends heavily on its ColoAlert screening tests.
• The company may face difficulties protecting its interests, and its ability to protect its rights through the U.S. federal courts may be limited because it is incorporated under the laws of the Netherlands.
• Global economic conditions could materially adversely impact demand for the company's products and services.
• The market price of the company's ordinary shares may be volatile and may fluctuate in a way that is disproportionate to its operating performance.
• The company is a foreign private issuer within the meaning of the rules under the Exchange Act, and as such it is exempt from certain provisions applicable to U.S. domestic public companies.

Future Outlook

The company intends to make its next generation colorectal cancer screening product the global CRC screening market leader by providing the best performance at an affordable cost.

Management Comments

• The company is focusing on expanding its ColoAlert business in Europe, the development of its next generation product, and planning for the Early Detect 2 clinical study in the U.S. in 2025.
• The company believes that these cost reductions will best position our business for 2025 and beyond.

Industry Context

The company competes with other entities developing and offering diagnostic tests to detect the presence of cancers, with its core product being a CRC screening stool DNA test and research underway for a similar test for pancreatic cancer.

Comparison to Industry Standards

• The company competes with Exact Sciences' Cologuard, a fecal DNA-based CRC screening test with a sensitivity of 92% and specificity of 87%, and an average reimbursement rate of $500.
• The company also competes with Freenome Holdings, Inc., Geneoscopy Inc., Guardant Health, Inc., GRAIL, Inc., and Universal DX, all of which are developing or offering CRC screening tests.
• The company believes that its strategic emphasis on decentralized laboratory testing, leveraging well-established PCR methodology allows it to position competitively against many firms adopting centralized testing models with costlier technologies like next-generation sequencing and mass spectrometry.

Legal Proceedings

• On March 22, 2024, the company filed a complaint in the Supreme Court of the State of New York against a former underwriter for breach of contract, unjust enrichment, and a declaratory judgment.
• The former underwriter brought an arbitration against the company seeking to collect alleged unpaid compensation for alleged financial services plus shares and warrants pursuant to two agreements.
• The company applied to the Arbitration Panel for an order staying the Arbitration proceeding pending final determination by the courts of the issues raised in the Supreme Court case, which was granted on September 12, 2024.

Related Party Transactions

• The company had revenue from related party of $61,569 for the year ended December 31, 2024.
• As of December 31, 2024, the company recorded accounts receivable related party of $17,238 and accounts payable related party of $10,399.
• As at December 31, 2024, EUR 200,000 (approximately $208,080) with a carrying value of $263,353 of the 8.5% SPAs were owing to major shareholders of the company.
• The company entered into a License and Option Agreement with Liquid Bioscience, Inc. to access a portfolio of novel mRNA biomarkers for the non-invasive detection of pancreatic cancer with a blood test.

Stakeholder Impact

• Shareholders may experience dilution of their ownership interests if the company issues additional ordinary shares or preferred shares.
• Employees were impacted by the company's restructuring, which included a reduction of personnel by 65%.
• Customers may benefit from the company's focus on expanding its ColoAlert business in Europe and preparing for U.S. market entry, which could lead to improved access to diagnostic tests.
• Suppliers may be affected by the company's cost reduction efforts, which included a reduction of external consulting costs.

Next Steps

• Expanding the commercial opportunity of the ColoAlert product in Europe by expanding the commercial team and partnerships.
• Preparing and executing a comprehensive clinical and regulatory strategy to achieve market authorization from the FDA to use the next generation colorectal cancer product as a screening test for CRC in the United States.
• Continuing research and development of PancAlert and the recently licensed blood-based biomarkers for the detection of pancreatic cancer.

Key Dates

Keywords

ColoAlert, Mainz Biomed, Colorectal cancer screening, Diagnostic tests, Pancreatic cancer, IVD, Financial results, Biomarkers